Typev A News Today

Metagenomi says the oversubscribed $175 million Series B financing it completed Tuesday will enable it to advance its lead in vivo and ex vivo gene editing therapy programs into the clinic.

 E-Mail IMAGE: outstanding research and commentary on all aspects of CRISPR and gene editing, including CRISPR biology, technology, and genome editing, and commentary and debate of key policy, regulatory, and ethical issues... view more  Credit: Mary Ann Liebert, Inc., publishers The CRISPR Journal announces the publication of its December 2020 issue, a Special Issue on Expanding the CRISPR Toolbox. The Journal is dedicated to validating and publishing outstanding research and comment...